|
Hepatitis B e antigen (HBeAg) seroconversion
|
Host factors
| |
| |
Puberty onset
|
[19, 20]
|
| |
Steroid 5-alpha reductase type II
|
[19]
|
| |
Dehydroepiandrosterone sulphate
|
[26]
|
| |
Human leukocyte antigen (HLA)-B61 and HLA-DQB1*0503
|
[39]
|
| |
Interleukin-10 and 12
|
[42]
|
| |
Toll-like receptor-5 and -9
|
[43]
|
| |
Furin
|
[68, 69]
|
| |
Program death 1 and program death ligand-1 pathway
|
[46, 48, 70]
|
| |
Virus factors
| |
| |
HBV Genotype
|
[40–52]
|
| |
HBV mutant strains (core-promotor, precore, core gene)
|
[54, 57, 58, 67]
|
| |
HBV viral load
|
[26]
|
|
HBV viral titer decrement
|
Host factors
| |
| |
Puberty onset
|
[19]
|
| |
Dehydroepiandrosterone sulphate
|
[26]
|
| |
Virus factors
| |
| |
HBV mutant strains (core-promotor, precore, core gene)
|
[54, 57, 58, 67]
|
|
Hepatitis B surface antigen (HBsAg) seroclearance/seroconversion
|
Host factors
| |
| |
Dehydroepiandrosterone sulphate
|
[26]
|
| |
Gut microbiota
|
[47]
|
| |
Menarche onset (in females)
|
[20]
|
| |
HLA (DRB1*1301-02, DR2, DR7, DR*0406, B*4001, DPA1 and DPB1)
|
[33–38]
|
| |
Interleukin-10 and 12
|
[45]
|
| |
Tumor necrosis factor alpha
|
[41]
|
| |
Toll-like receptor-4
|
[43, 47]
|
| |
Program death 1 and program death ligand-1 pathway
|
[46, 48, 70]
|
| |
Breakthrough of immune tolerance
|
[45]
|
| |
HBeAg seroconversion at childhood
|
[45]
|
| |
Virus factors
| |
| |
HBV viral load
|
[45]
|
| |
HBsAg titer
|
[45]
|
|
HBeAg-negative hepatitis
|
HBeAg seroconversion age
|
[10–12, 60, 75]
|
| |
HBV mutant
|
[57, 75]
|
